Navigation Links
FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimer's Disease (AD)
Date:3/26/2008

BOSTON, March 26 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) market, announced that it has entered into a licensing agreement with Massachusetts General Hospital (MGH) for the development and commercialization of agents for diagnosis and treatment of Alzheimer's disease (AD). The licensed technologies, which were co-developed by FluoroPharma and MGH scientists, target multiple biological processes associated with AD. Currently, there is no single diagnostic test that proves a person has AD. Development of new options for early detection and treatment of Alzheimer's has the potential to improve patient care and create new paths for AD management for the more than 5M Americans that suffer from dementia and other cognitive deficits as a result of AD.

"Our molecular imaging approach to AD includes multiple molecular compositions that target AD associated phenomena -- low acetylcholine and amyloid plaque formation. With some agents, it may be possible to improve brain function by inhibiting the breakdown of acetylcholine, and with others we may be able to prevent the formation of amyloid plaque by inhibiting protein misfolding. As PET imaging tracers, these agents also have potential applications in both diagnosis of the disease and monitoring of the therapy, by differentially accumulating in regions of the brain affected by the disease compared to normal brain tissue," explained Dr. David Elmaleh, FluoroPharma's Chairman and Scientific Founder.

"The technology has the potential to be highly effective due to the agents' enhanced accumulation in the brain," said Dr. Kundakovic, FluoroPharma's President. "As PET imaging agents, these compounds may provide valuable information in patients where early diagnostic and therapeutic information is likely to have the greatest benefit."

About FluoroPharma

FluoroPharma is a molecular imaging company engaged
'/>"/>

SOURCE FluoroPharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Honeywell Expands Aclar(R) Production for Pharmaceutical Industry
2. Murad Expands International Presence With Appointment of Danny Guez
3. Sigma-Aldrich Amends Credit Facility and Expands Commercial Paper Program
4. VIE Healthcare Expands Its Operations in the Midwest, and Obtains First Local Client
5. Eating Disorders Program at Lucile Packard Childrens Hospital Expands to Include Young Adults
6. Dollar Thrifty Automotive Group Expands Mobile Managed Services Contract with InfoLogix
7. Life Spine Expands Home Office Space, More Than Doubling Space Occupied
8. Millennium Expands IBD Franchise with Addition of New Development Candidate
9. inVentiv Clinical Expands Operations to Emerging Latin American Region
10. Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally
11. AlphaDetail, Inc. Expands Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...July 24 /PRNewswire-USNewswire/ -- Steven Mosher,...I), says that America has,a hidden problem of sex ...feminists refuse to address., In PRI,s latest You...,East and South Asian countries, of sex-selective ...actice has already claimed the lives of over 100,m...
(Date:7/24/2008)...July 24 /PRNewswire/ -- A new alliance of animal,l...roblems -- obesity -- in,pets and pet owners., Am...ne third of us are,obese, including 9 million chil...ok like us -- mirror us with similar health issues...partnership that includes,Harvard Medical Center, ...
(Date:7/24/2008)... CosmetaLife clinical trial results could lead ...cost-effective treatment for deep lines and wrinkl...inn. (PRWEB) July 24, 2008 -- Gel-Del Technologie...company announced that it has concluded clinical t...at company officials say holds potential to be a m...
(Date:7/24/2008)...RNewswire-FirstCall/ --, Key Highlights, Misys p...ns and is now,raising targets for the next phase o...) of GBP492m up 6%, bringing Group operating profi...xecuting on its strategy and entering,into the nex...m for growth., To view the Multimedia News Releas...
Breaking Medicine News(10 mins):Health News:PRI: Pro-Life Leader Blames Feminist Groups for Slaughter of Girls 2Health News:PetFit Challenge Helps Keep Pets - and Pet Owners - Healthy 2Health News:Clinical Trial Concluded For New Wrinkle Treatment 2Health News:Clinical Trial Concluded For New Wrinkle Treatment 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 2Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 4
...tudy suggests that eating more fiber and fruit eac...he study is based on the results of examining the ...ht or obese adults. The study found that normal w...dietary fiber and 43 percent more complex carbohyd...
...n Saturday reported a new outbreak of bird flu amo... Xinjiang.// The national avian influenza laborat...he H5N1 avian influenza virus, stemming from an ou...4 near the town of Aksu, the agriculture ministry ...
...Food and Drug Administration (FDA) gave approval t...e matchstick sized contraceptive is implanted bene...regnancy for three year after which it may be repl...Implanon said that the implant would release a low...
... (tigecycline)is a new, expanded broad-spectrum IV...a wide range of infections including those caused ...llin-resistant Staphylococcus aureus (MRSA). It wi...y of this new antibiotic comes at a time when the ...
Other Medicine News:Health News:Broad Spectrum Antibiotic Available for Antibiotic Resistant Bacteria 2
(Date:7/22/2008)... the Importance to Patients of Passing a ...HMOND, Va., July 22 /- Insm... biologics and biopharmaceuticals, today,announced...resent at a,Congressional briefing on Friday, July...tablishing an approval pathway for follow-on,biolo...
(Date:7/22/2008)...y 22 /- NicOx S.A.,(Euronex...completed the,enrollment of 417 osteoarthritis (OA...nical pharmacology studies in the United States, i...trials are designed to assess the,blood pressure p...and,naproxen, using the Ambulatory Blood Pressure ...
(Date:7/21/2008)...-- The University of Oxford Clinical Trial,Service...osed that the,hypothesis-generating results of the...wing the combined cancer results from the SHARP an... the overall findings to,the relevant regulatory a...s., The two hypothesis-testing trials (SHARP and ...
(Date:7/21/2008)... clinicians identify risk in patients, includin...tin therapy, BIRMINGHAM, Ala., July 21 /PRNewswir...ch, researchers have identified a link between,adi...ation could help,physicians trying to pinpoint the...-lowering treatments in at-risk patients., The as...
Breaking Medicine Technology:Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 2Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 3VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis 2VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis 3Sex is thirst quenching for female beetles 165 1Sex is thirst quenching for female beetles 165 2Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns Australia 213 1Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns Australia 213 2KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates 210 1KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates 210 2Advanced Life Sciences Announces ALS 357 Granted FDA Orphan Drug Designation for Metastatic Melanoma 149 1Advanced Life Sciences Announces ALS 357 Granted FDA Orphan Drug Designation for Metastatic Melanoma 149 2Advanced Life Sciences Announces ALS 357 Granted FDA Orphan Drug Designation for Metastatic Melanoma 149 3Advanced Life Sciences Announces ALS 357 Granted FDA Orphan Drug Designation for Metastatic Melanoma 149 4
...imaging technique suggests how lithium works as a,...ientists at UCLA have shown,that lithium, long the...s the amount of gray matter in the brains of patie... in the July issue of the journal,Biological Psych...e Bearden, a clinical neuropsychologist and assist...
...May Provide Cancer Patients With Improved Potentia... 16, 2007 /PRNewswire/ -- Insert,Therapeutics, Inc...ch Corporation announced today its novel delivery ...poster presentation at,the 2007 American Associati...articular, this poster includes new research findi...
Other Medicine Technology:UCLA: Lithium Builds Gray Matter in Bipolar Brains, UCLA Study,Shows 2UCLA: Lithium Builds Gray Matter in Bipolar Brains, UCLA Study,Shows 3Poster on Cyclosert Drug Delivery Presented at AACR Meeting 2Poster on Cyclosert Drug Delivery Presented at AACR Meeting 3Poster on Cyclosert Drug Delivery Presented at AACR Meeting 4
Operating Microscope with excellent maneuverability. Konan made it compact and light weight maintaining high quality. Easy switchover from straight to oblique by simply changing the adapter. Konan's
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure.
With side bite Instrument recommended to catch the polypropylene thread in the nose.
Instrument necessary for insertion of Ritleng Bicanaliculus systems and of Self-Threading Monoka systems.
Medicine Products: